Scientists Find Way to Stop Virus Affecting 95% of People
- Scientists at Fred Hutch Cancer Center reported an important advance on April 15, 2026, in the effort to stop the Epstein-Barr virus (EBV).
- The discovery targets the neutralization of EBV, a widespread virus associated with health categories including leukemia and lymphoma.
- As research progresses from laboratory discovery to public health application, the scientific community utilizes specific metrics to determine how well a new medical intervention works.
Scientists at Fred Hutch Cancer Center reported an important advance on April 15, 2026, in the effort to stop the Epstein-Barr virus (EBV). The research focuses on neutralizing a virus that is believed to infect approximately 95% of people worldwide.
The discovery targets the neutralization of EBV, a widespread virus associated with health categories including leukemia and lymphoma.
Evaluating Medical Breakthroughs
As research progresses from laboratory discovery to public health application, the scientific community utilizes specific metrics to determine how well a new medical intervention works. According to the World Health Organization, it is essential to distinguish between vaccine efficacy and vaccine effectiveness.
Vaccine efficacy is measured within controlled clinical trials. This metric is based on the number of vaccinated individuals who develop a specific outcome, such as a disease, compared to the number of people in a placebo group who develop the same outcome. Efficacy indicates how much an intervention lowers the risk of a disease in a trial setting.
In contrast, vaccine effectiveness refers to how well the intervention performs in the real world. While clinical trials include a broad range of ages, sexes and ethnicities, they cannot perfectly represent the entire population. Effectiveness can differ from efficacy because real-world conditions involve a much larger and more variable population.
Before any such medical advance is approved by regulatory agencies, it must undergo rigorous clinical trials to test its quality, safety, and efficacy. Following approval, these interventions continue to be monitored for ongoing safety and effectiveness.
The World Health Organization also notes that viruses and bacteria can change over time, which can lead to new variants that spread more easily or cause more severe disease. This requires continuous monitoring and updated guidance to ensure that medical protections provide the best possible results.